References
- Abrams P, Artibani W, Cardozo L, et al. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006;25:293
- Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15
- Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health 2004;7:455-63
- MacDiarmid S, Rosenberg M. Overactive bladder in women: symptom impact and treatment expectations. Curr Med Res Opin 2005;21:1413-21
- Coyne KS, Margolis MK, Jumadilova Z, et al. Overactive bladder and women's sexual health: what is the impact?. J Sex Med 2007;4:656-66
- Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006;97:96-100
- Stach-Lempinen B, Hakala AL, Laippala P, et al. Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn 2003;22:563-8
- van der Vaart CH, de Leeuw JR, Roovers JP, et al. The effect of urinary incontinence and overactive bladder symptoms on quality of life in young women. BJU Int 2002;90:544-9
- Mehta A, Bachmann G. Premenopausal women with sexual dysfunction: the need for a bladder function history. J Sex Med 2008;5:407-12
- Brubaker L, Chapple C, Coyne KS, et al. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology 2006;68:3-8
- Coyne KS, Matza LS, Kopp Z, et al. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
- Coyne KS, Elinoff V, Gordon DA, et al. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. Int J Clin Pract 2008;62:925-31
- Pleil AM, Coyne KS, Reese PR, et al. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue – BSW. Value Health 2005;8:S25-34
- Cardozo L, Coyne KS, Versi E. Validation of the Urgency Perception Scale. BJU Int 2005;95:591-6
- van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-21
- Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. World J Urol 2004;22:251-6
- Kelleher CJ, Reese PR, Pleil AM, et al. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002;8:S608-15
- Rogers R, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:1551-7
- Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
- Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn 1995;14:131-9
- Coyne KS, Matza LS, Thompson CL, et al. Determining the importance of change in the overactive bladder questionnaire. J Urol 2006;176:627-32
- Khullar V, Hill S, Laval K-U, et al. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 2004;64:269-75
- Dmochowski R, Abrams P, Marschall-Kehrel D, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054-64
- Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003;62:237-42